{"id":"W4251804183","doi":"10.1093/ibd/izy393.049","title":"01 DOSE ESCALATION WITH ORIGINATOR INFLIXIMAB IS MORE COMMON THAN STANDARD DOSING IN PEDIATRIC IBD – THE DEVELOP EXPERIENCE","year":2019,"lang":"en","type":"article","venue":"Inflammatory Bowel Diseases","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Infliximab; Inflammatory bowel disease; Ulcerative colitis; Internal medicine; Observational study; Population; Dosing; Clinical trial; Disease; Pediatrics","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":{"n_in":0,"stratum":"about_only","weight":3321.24,"opus":{"tier":"OUT","genre":"empirical","about_ca":false,"confidence":"high","reason":"Registry analysis of infliximab dose escalation in pediatric IBD; clinical question."},"gpt":{"tier":"OUT","genre":"empirical","about_ca":false,"confidence":"high","reason":"The registry study examines infliximab dosing in pediatric inflammatory bowel disease."},"grok":{"tier":"OUT","genre":"empirical","about_ca":false,"confidence":"high","reason":"Observational registry of infliximab dosing in pediatric IBD; clinical therapeutics."}}}